COMMUNIQUÉS West-GlobeNewswire

Vystar Plans Dividend Spin Off of RXAIR and Related Brands Following R3alm, Inc. Transaction
27/04/2026
Vystar Announces Strategic Direction for Vytex, FEC, and RXAIR BOSTON, MA, April 27, 2026 (GLOBE NEWSWIRE) -- Vystar Corporation (OTCQB: VYST) is focusing the majority of its resources on R3alm.com , which, is building [...]
TerrAscend Announces Preliminary First Quarter 2026 Financial Results and Schedules Earnings Conference Call
27/04/2026
First Quarter 2026 Net Revenue Totaled $65.5 million with Gross Profit Margin of 52.8% TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF) , a leading [...]
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
27/04/2026
Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma Pivotal study expected to focus on patients in a post-standard-of-care patient population with no [...]
Every minute counts: EAACI calls for urgent action to make schools safe for children at risk of anaphylaxis
27/04/2026
At the Spanish Congress of Deputies, EAACI President María José Torres backed a joint manifesto with AEPNAA, SEAIC, and SEICAP, calling for urgent action on school protocols, staff training, and access to life-saving [...]
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
27/04/2026
ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing, with longer-term [...]
Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma
27/04/2026
Single agent duvelisib demonstrated clinically meaningful response rates, including a substantial proportion of complete responses, in a heavily pretreated PTCL population Responses highest in angioimmunoblastic T-cell [...]
Seer Board of Directors Unanimously Rejects Revised Unsolicited Proposal from Radoff-JEC Group
27/04/2026
Board Determines Proposal Significantly Undervalues Seer and Is Not in the Best Interests of Stockholders REDWOOD CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the [...]
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
27/04/2026
Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from both attacks and [...]
Conference to focus on how artificial intelligence can dramatically reduce workplace injuries
27/04/2026
MARKHAM, Ontario, April 27, 2026 (GLOBE NEWSWIRE) -- The third annual New Horizons in Safety Summit - From Outputs to Outcomes - to be hosted by 4S Consulting will be held on May 7 th . . The conference will bring [...]
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
27/04/2026
― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) [...]
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
27/04/2026
Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand’s long-term compounding growth, adding a complementary portfolio across [...]
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences
27/04/2026
BEDFORD, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation [...]
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity
27/04/2026
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today [...]
Sagimet Biosciences Provides Strategic and Corporate Updates
27/04/2026
Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Further MASH [...]
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
27/04/2026
Expect to complete BLA submission in second half of 2026; anticipate launch in first half of 2027, if approved CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading [...]
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
27/04/2026
Patent expected to be formally granted within three months, subject to standard administrative procedures Patent would provide exclusivity at least into 2039 for stenoparib when used in concert with the stenoparib DRP [...]
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
27/04/2026
Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand’s long-term compounding growth, adding a complementary portfolio across [...]
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026
27/04/2026
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on May 12, 2026 NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease [...]
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
27/04/2026
Topline data is on track for anticipated readout in the summer of 2026 WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission [...]

Pages